The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.

@article{AbdelQadir2016TheRO,
  title={The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.},
  author={Husam Mohamed Abdel-Qadir and Eitan Amir and Hadas D. Fischer and Longdi Fu and Peter C. Austin and P. J. Harvey and Paula Rochon and Douglas S Lee and Geoffrey M. Anderson},
  journal={European journal of cancer},
  year={2016},
  volume={68},
  pages={11-21}
}
BACKGROUND Aromatase inhibitors (AIs) may increase cardiovascular risk relative to tamoxifen in post-menopausal women with breast cancer. This risk has not been well-quantified outside of clinical trials. METHODS Observational population-based cohort study of women aged >55 years diagnosed with stage I-III breast cancer between 2005 and 2010. Women treated with AIs or tamoxifen were followed to March 2012. The primary outcome was hospitalisation for myocardial infarction (MI). Cause-specific… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Early Breast Cancer Trialists

  • Group, M Dowsett, +4 authors J Bliss
  • Lancet 2015 Oct 3;386(10001):1341e52
  • 2015
2 Excerpts

Similar Papers

Loading similar papers…